Introduction
The diagnosis and classification of acute leukemias rely on morphology, immunophenotyping with the expression of surface or cytoplasmic (cy) antigens, chromosomal abnormalities, and specific molecular genetic analyses. The classification of acute leukemias established by the French-AmericanBritish (FAB) Cooperative Study Group has long been used, being based on traditional morphologic and cytochemical criteria 1) . The FAB classification also includes minimally differentiated acute myeloid leukemia (AML-M0), where the criteria consist of the presence of less than 3% myeloperoxidase (MPO) -and/or sudan black-B-positive blasts in the bone marrow by light microscopy, at least one myeloid-associated antigen positivity (CD13 and/or CD33), and the absence of lymphoid antigens, with the exception of TdT and CD7 2) . In addition, an immunocytochemistry and/or electron microscopy analysis with MPO expression is optional 2) , but the latter is by no means practical. There are some cases where the lineage origin of leukemic blasts cannot be established by the associations of morphology, cytochemistry, and immunophenotyping with an extensive panel of monoclonal antibodies, leading to the tentative category of acute undifferentiated leukemia (AUL), which is unclassifiable by the FAB classification 3) -5) . The European Group for the Immunological Characterization of Leukemias (EGIL) also recognized a rare subtype of acute leukemias as ʻundifferentiated acute leukemiasʼ, where the leukemic cells do not express lineage-specific markers 6) . In this paper, we report a rare case of therapy-related AML, in which MPO expression in the patientʼs leukemic cells was confirmed only by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis and not immunophenotyping. Our observations suggest the need for further emphasis on molecular analysis of lineage markers in leukemia diagnosis.
Case report
The patient was an 88-year-old male who presented with anemia in October 2009. Two years before admission to the hospital, he had been treated with 6 courses of the R-CHOP chemotherapy regimen for nasopharyngeal non-Hodgkinʼs lymphoma (NHL) and achieved complete remission (CR) in another hospital. Hematologic findings upon admission were: hemoglobin (Hb), 5.9 g/dL; platelets, 74 × 10 9 /L;
and white blood cells (WBC), 28.1 × 10 9 /L with 1% band-form neutrophils, 46% segmented neutrophils, 1% eosinophils, 3% monocytes, and 49% lymphocytes. A bone marrow aspirate showed hypocellularity with 31.0% blasts, 1.8% promyelocytes, 1.8% myelocytes, 1.6% metamyelocytes, 10.0% neutrophils, 0.6% eosinophils, 26.8% lymphocytes, 4.0% monocytes, 1.8% plasma cells, and 18.6% erythroblasts. As shown in Figure- 1A, blasts were characterized by a large size, modest amount of cytoplasm without granules, and prominent nucleolus. No dysplastic change was observed in the erythroid, megakaryocytic, or granulocytic/monocytic lineages. The cytochemistry of blasts showed negativity for MPO and esterase stain.
Immunophenotyping of bone marrow cells at diagnosis was performed using two-color flow cytometry and a panel of monoclonal antibodies. Labeled cells were analyzed after the blast cell population was gated in a dot plot displaying the linear forward (FSC) and side scatter (SSC) properties of the cells. We used a CD45 intensity expression with right-angle light scatter to detect leukemic blasts and separate them from the normal bone marrow populations 9) ( Figure 1-B) . Antigen expression was considered positive if 20% or more of blast cells reacted with a particular antibody 10) . As shown in Figure- 1B, leukemic cells of the patient were positive for CD34 (75%), CD117 (93%), and HLA-DR (88%) antigens (none are lineage-specific), but negative for CD13 (15%) and CD33 (3%) antigens (both are myeloid markers). The percentage of cyMPOpositive cells was 4.6% (being negative) with gaiting set for whole mononuclear cells (Figure-1C ) and 19.2% with gating set for larger blast cell populations (Figure-1D) . The fluorescence intensity of cyMPO expression was very weak, displaying a position near the negative control (Figure-1E ).
Immunophenotyping by flow cytometry may be operator-dependent, especially in the case of cytoplasmic antigen expression. In this case, whereas the cyMPO expression provides evidence of myeloid lineage commitment 11) , the faint cyMPO expression in the patientʼs leukemic blasts was inconclusive for establishing a myeloid origin.
Cytogenetic analysis of bone marrow cells by conventional G-banding showed 47, XY, + 8, inv (9) (p12q13) in 3 out of 20 metaphase cells analyzed ( Figure-2A) , and the remaining 17 cells were 46, XY, inv (9)(p12q13), where the latter was considered to be a normal variation. To confirm the presence of trisomy 8, we performed fluorescence in situ hybridization (FISH) analysis using the CEP 8 SpectrumOrange Direct Labeled Fluorescent DNA Probe Kit (Abbott Laboratories, Abbott Park, IL, USA), as described previously 12) . As shown in Figure-2B , a three-orange signal pattern was detected in 35% of the interphase nuclei analyzed, indicating the presence of trisomy 8.
Taking account of the inconclusive cyMPO expression, we performed qRT-PCR analysis. Total RNA was extracted from bone marrow cells using the RNeasy Mini Kit (Qiagen, Maryland, CA, USA). GTC GCA GA-3ʼ; MPO-2 forward: 5ʼ -TAC CAG GAA GCC CGG AAG AT-3ʼ, reverse: 5ʼ-TGA GTC ATT GTA GGA ACG GTA CGT G-3ʼ; and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward: 5ʼ-GCA CCG TCA AGG CTG AGA AC-3ʼ, reverse: 5ʼ -TGG TGA AGA CGC CAG TGG A-3ʼ. qRT-PCR analysis showed MPO gene expression in the bone marrow cells of the patient, compared with the positive control of HL60 and buffy coat cells and the negative control of K562 cells (Figure-3A) . The relative expression of the MPO gene was near the same level as in HL-60 cells when both MPO-1 and MPO-2 primers were used (Figure-3B ). These findings suggest that the leukemic blasts of the patient might be an earlier myeloid differentiation stage before the full expression of myeloid markers. The patient was treated with AML-directed combination chemotherapy and achieved CR. In September 2010, the patient was readmitted to the hospital because of recurrence of the disease. He received salvage chemotherapy, but became refractory to it, and died of disease progression and sepsis in January 2011.
Discussion
Among the various types of AML, AML-M0 is regarded as a relatively rare disorder with an incidence of 2-4% 13) . AML-M0 blasts exhibit large and agranular features, and frequently lack those of a specific cell lineage, precluding diagnosis on morphological grounds alone 2) . The criteria include the expression of at least one myeloid-associated antigen (CD13 and/or CD33) 2) . As for MPO expression, cyMPO antigens may be positive by immunophenotyping with anti-MPO monoclonal antibodies. In the present case, leukemic blasts were positive for CD34, CD117, and HLA-DR antigens, but negative for CD13 and CD33 antigens, and showed faint cyMPO expression with weak fluorescence intensity. The latter might be inconclusive as evidence of myeloid differentiation. The immature nature of leukemic blasts has been associated with the expression of markers for hematopoietic progenitor cells, such as CD34, CD117, and HLA-DR 14) . Although the diagnosis of the present case was initially considered as AUL, qRT-PCR analysis revealed MPO gene expression, being of myeloid origin and presumably categorized as AML-M0. These findings suggest that immunophenotyping alone might not be sufficient for establishing a diagnosis of acute leukemias with immature phenotypes. The diagnosis and classification of acute leukemias affect patient management options. The prognosis of AUL patients is generally considered as poor, although the information is too scanty to make any definitive statements 7) . AML-M0 has also been reported to be associated with a poor prognosis compared with non-M0 counterparts 13) 15)- 17) . Factors that may be responsible for the poorer prognosis include the high frequency of unfavorable cytogenetic changes, the high expression of immature markers, and the frequent expression of multidrug resistance protein 13) 18) . Furthermore, treatment outcomes in AML patients continuously decline with aging 19) . In the present case, our patient was an 88-year-old male with prior chemotherapy for NHL and his leukemic blasts exhibited an immature phenotype. The diagnosis of AML was made by qRT-PCR analysis and he achieved CR with AMLdirected intensive chemotherapy.
In conclusion, qRT-PCR analysis successfully detected MPO gene expression in the patientʼs leukemic cells. Our observations suggest the usefulness of qRT-PCR analysis of lineage markers in leukemia diagnosis.
